Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PASG 
Passage Bio Inc (PASG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: PASG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $59.25
1 Year Target Price $59.25
| 5 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.75% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 22.25M USD | Price to earnings Ratio 0.18 | 1Y Target Price 59.25 |
Price to earnings Ratio 0.18 | 1Y Target Price 59.25 | ||
Volume (30-day avg) 5 | Beta 1.82 | 52 Weeks Range 5.12 - 26.60 | Updated Date 09/16/2025 |
52 Weeks Range 5.12 - 26.60 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 39.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -33.2% | Return on Equity (TTM) -88.27% |
Valuation
Trailing PE 0.18 | Forward PE - | Enterprise Value -10644030 | Price to Sales(TTM) - |
Enterprise Value -10644030 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.87 | Shares Outstanding 3178710 | Shares Floating 2867165 |
Shares Outstanding 3178710 | Shares Floating 2867165 | ||
Percent Insiders 0.21 | Percent Institutions 54.5 |
Upturn AI SWOT
Passage Bio Inc
Company Overview
History and Background
Passage Bio, Inc. was founded in 2017. It focused on developing gene therapies for central nervous system disorders. However, in 2023, it announced it was discontinuing clinical development and exploring strategic alternatives.
Core Business Areas
- Gene Therapy Development: Formerly Passage Bio's primary focus was on developing AAV-delivered gene therapies for rare monogenic central nervous system disorders. All clinical development has ceased.
Leadership and Structure
The company structure comprised a Board of Directors and an executive management team. As of late 2023, the future structure is uncertain given the company's wind-down strategy.
Top Products and Market Share
Key Offerings
- PBGM01 (GM1 gangliosidosis): Previously Passage Bio's lead product candidate, but development was discontinued. There is limited market share data available since the product was still in clinical trials. Competitors included companies working on gene therapies and other treatments for GM1 gangliosidosis.
- PBML040 (Metachromatic Leukodystrophy): Formerly in development by passage Bio as a treatment for Metachromatic Leukodystrophy, but development was discontinued. There is limited market share data available since the product was still in clinical trials. Competitors included companies working on gene therapies and other treatments for MLD.
Market Dynamics
Industry Overview
The gene therapy industry is a rapidly evolving field focused on treating diseases at the genetic level. It faces significant regulatory hurdles, high development costs, and competition.
Positioning
Passage Bio was a clinical-stage company focusing on rare neurological diseases. Its positioning was challenged by clinical setbacks and financial constraints.
Total Addressable Market (TAM)
The total addressable market for gene therapies in rare neurological diseases is substantial, potentially billions of dollars. Passage Bio's position was limited by its early stage of development and subsequent discontinuation of programs.
Upturn SWOT Analysis
Strengths
Weaknesses
- Discontinued clinical development
- Uncertain future business model
- Limited financial resources
Opportunities
- Potential for asset sales or licensing agreements
- Strategic partnership opportunities
Threats
- Failure to find a suitable strategic alternative
- Further decline in stock price
- Liquidation
Competitors and Market Share
Key Competitors
- BLUE
- CRIS
- SRPT
Competitive Landscape
Passage Bio's competitive position has weakened significantly due to the discontinuation of its clinical programs. Its competitors have stronger pipelines and financial resources.
Growth Trajectory and Initiatives
Historical Growth: Passage Bio initially showed promise in the gene therapy space but failed to achieve sustainable growth.
Future Projections: Future projections are highly uncertain due to the company's strategic shift and discontinuation of clinical programs.
Recent Initiatives: Recent initiatives involve exploring strategic alternatives, including potential asset sales.
Summary
Passage Bio has significantly weakened after discontinuing clinical development and seeking strategic alternatives. The company faces considerable uncertainty, and its future depends on finding a viable strategic option. It previously showed potential in the gene therapy space, but has been unable to achieve commercial success, putting it behind its competitors. Currently, its long-term viability is very questionable.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Press releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The information is subject to change and may not be comprehensive.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Passage Bio Inc
Exchange NASDAQ | Headquaters Philadelphia, PA, United States | ||
IPO Launch date 2020-02-28 | President, CEO & Director Dr. William Chou M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 60 | Website https://www.passagebio.com |
Full time employees 60 | Website https://www.passagebio.com | ||
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.